Edgewise Therapeutics CFO Michael Nofi sells $201,786 in shares

Edgewise Therapeutics CFO Michael Nofi divested 4,442 of the company's shares on November 10, 2026, generating a total of $201,786. The shares traded within a range of $45.165 to $45.57, with an average price of $45.427. Despite the sale, Edgewise's stock currently trades at $46.53, marking a 117% year-to-date gain, and is just 0.95% below its 52-week high of $48.78.

The transactions were executed to satisfy tax obligations for the vesting of restricted stock units (RSUs), and not as a discretionary decision by Nofi. Simultaneously, Nofi acquired 10,937 shares of the company through the vesting of RSUs, increasing his direct beneficial ownership to 6,495 shares and 32,813 derivative securities.

Edgewise Therapeutics remains financially robust, with liquid assets surpassing short-term obligations. The company has recently made significant strides, including the presentation of Phase 1 data for EDG-15400 at the Heart Failure Society of America meeting and the sale of its Sevasemten and muscular dystrophy business to Servier for $1.55 billion.

Analysts are optimistic about EDG-7500, with Raymond James raising the price target to $85.00 and maintaining a Strong Buy rating, while William Blair initiated coverage with an outperform rating and a discounted cash flow (DCF) valuation of $53 per share. H.C. Wainwright also reiterated a Buy rating with a $57.00 price target. Upcoming Phase III studies for EDG-7500 are set to commence in obstructive and nonobstructive hypertrophic cardiomyopathy in late 2026.